A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cha, R.-H. | - |
dc.contributor.author | Kang, S.W. | - |
dc.contributor.author | Park, C.W. | - |
dc.contributor.author | Cha, D.R. | - |
dc.contributor.author | Na, K.Y. | - |
dc.contributor.author | Kim, S.G. | - |
dc.contributor.author | Yoon, S.A. | - |
dc.contributor.author | Han, S.Y. | - |
dc.contributor.author | Chang, J.H. | - |
dc.contributor.author | Park, S.K. | - |
dc.contributor.author | Lim, C.S. | - |
dc.contributor.author | Kim, Y.S. | - |
dc.date.accessioned | 2021-09-04T08:48:53Z | - |
dc.date.available | 2021-09-04T08:48:53Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1555-9041 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/91368 | - |
dc.description.abstract | Background and objectives The notion that oral intestinal sorbent AST-120 slows renal disease progression has not been evaluated thoroughly. In this study, we investigated the long-term effect of AST-120 on renal disease progression (doubling of serum creatinine, eGFR decrease >50%, or initiation of RRT) in patients with advanced CKD. Design, setting, participants, & measurements We prospectively recruited 579 patients (CKD stage 3 or 4) from 11 medical centers in Korea from March 4, 2009 to August 31, 2010 and randomized them into an AST-120 arm and a control arm. Patients in the AST-120 arm were given 6 g AST-120 in three divided doses per day, and those in the control arm received only standard conventional treatment (open-label design) for 36 months or until the occurrence of primary outcomes. Results Levels of serum and urine indoxyl sulfate and β2-microglobulin decreased throughout the study period in both treatment arms; however, there was not a significant difference in change in uremic toxins in the AST-120 and control arms. The two arms were not different in the occurrence of composite primary outcomes (100 events in 272 individuals in the AST-120 arm and 100 events in 266 individuals in the control arm; hazard ratio, 1.12; 95% confidence interval, 0.85 to 1.48; log-rank P=0.45). The decline in eGFR and change in proteinuria were similar in the two treatment arms over time (Prandomization–time =0.64 and Prandomization–time =0.16, respectively). There was no difference in mortality (nine deaths in the AST-120 arm and 11 deaths in the control arm; log-rank P=0.73) or unplanned hospitalizations (102 in the AST-120 arm and 109 in the control arm; log-rank P=0.76) in the two treatment arms. There was no significant difference of the health–related quality of life score between the two arms. Conclusions Long-term use of AST-120 added to standard treatment did not change renal disease progression, proteinuria, mortality, and health–related quality of life in patients with advanced renal dysfunction. © 2016 by the American Society of Nephrology. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | American Society of Nephrology | - |
dc.subject | ast 120 | - |
dc.subject | beta 2 microglobulin | - |
dc.subject | calcium channel blocking agent | - |
dc.subject | hemoglobin | - |
dc.subject | indican | - |
dc.subject | sorbent | - |
dc.subject | uremic toxin | - |
dc.subject | ast 120 | - |
dc.subject | carbon | - |
dc.subject | oxide | - |
dc.subject | adult | - |
dc.subject | Article | - |
dc.subject | autoinflammatory disease | - |
dc.subject | brain infarction | - |
dc.subject | constipation | - |
dc.subject | controlled study | - |
dc.subject | diabetic nephropathy | - |
dc.subject | diastolic blood pressure | - |
dc.subject | disease course | - |
dc.subject | drug safety | - |
dc.subject | drug withdrawal | - |
dc.subject | estimated glomerular filtration rate | - |
dc.subject | hazard ratio | - |
dc.subject | heart arrhythmia | - |
dc.subject | heart failure | - |
dc.subject | human | - |
dc.subject | inflammatory bowel disease | - |
dc.subject | kidney disease | - |
dc.subject | kidney function | - |
dc.subject | kidney polycystic disease | - |
dc.subject | kidney transplantation | - |
dc.subject | life expectancy | - |
dc.subject | liver cirrhosis | - |
dc.subject | loss of appetite | - |
dc.subject | major clinical study | - |
dc.subject | middle aged | - |
dc.subject | mortality | - |
dc.subject | nausea | - |
dc.subject | obstructive uropathy | - |
dc.subject | proteinuria | - |
dc.subject | quality of life | - |
dc.subject | randomized controlled trial | - |
dc.subject | renin angiotensin aldosterone system | - |
dc.subject | sample size | - |
dc.subject | serum | - |
dc.subject | transient ischemic attack | - |
dc.subject | vomiting | - |
dc.subject | chronic kidney failure | - |
dc.subject | clinical trial | - |
dc.subject | drug effects | - |
dc.subject | female | - |
dc.subject | kidney | - |
dc.subject | male | - |
dc.subject | multicenter study | - |
dc.subject | oral drug administration | - |
dc.subject | pathophysiology | - |
dc.subject | prospective study | - |
dc.subject | Administration, Oral | - |
dc.subject | Carbon | - |
dc.subject | Disease Progression | - |
dc.subject | Female | - |
dc.subject | Humans | - |
dc.subject | Kidney | - |
dc.subject | Kidney Failure, Chronic | - |
dc.subject | Male | - |
dc.subject | Middle Aged | - |
dc.subject | Oxides | - |
dc.subject | Prospective Studies | - |
dc.title | A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cha, D.R. | - |
dc.identifier.doi | 10.2215/CJN.12011214 | - |
dc.identifier.scopusid | 2-s2.0-85011582887 | - |
dc.identifier.bibliographicCitation | Clinical Journal of the American Society of Nephrology, v.11, no.4, pp.559 - 567 | - |
dc.relation.isPartOf | Clinical Journal of the American Society of Nephrology | - |
dc.citation.title | Clinical Journal of the American Society of Nephrology | - |
dc.citation.volume | 11 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 559 | - |
dc.citation.endPage | 567 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | ast 120 | - |
dc.subject.keywordPlus | beta 2 microglobulin | - |
dc.subject.keywordPlus | calcium channel blocking agent | - |
dc.subject.keywordPlus | hemoglobin | - |
dc.subject.keywordPlus | indican | - |
dc.subject.keywordPlus | sorbent | - |
dc.subject.keywordPlus | uremic toxin | - |
dc.subject.keywordPlus | ast 120 | - |
dc.subject.keywordPlus | carbon | - |
dc.subject.keywordPlus | oxide | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | autoinflammatory disease | - |
dc.subject.keywordPlus | brain infarction | - |
dc.subject.keywordPlus | constipation | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | diabetic nephropathy | - |
dc.subject.keywordPlus | diastolic blood pressure | - |
dc.subject.keywordPlus | disease course | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | drug withdrawal | - |
dc.subject.keywordPlus | estimated glomerular filtration rate | - |
dc.subject.keywordPlus | hazard ratio | - |
dc.subject.keywordPlus | heart arrhythmia | - |
dc.subject.keywordPlus | heart failure | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | inflammatory bowel disease | - |
dc.subject.keywordPlus | kidney disease | - |
dc.subject.keywordPlus | kidney function | - |
dc.subject.keywordPlus | kidney polycystic disease | - |
dc.subject.keywordPlus | kidney transplantation | - |
dc.subject.keywordPlus | life expectancy | - |
dc.subject.keywordPlus | liver cirrhosis | - |
dc.subject.keywordPlus | loss of appetite | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | mortality | - |
dc.subject.keywordPlus | nausea | - |
dc.subject.keywordPlus | obstructive uropathy | - |
dc.subject.keywordPlus | proteinuria | - |
dc.subject.keywordPlus | quality of life | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | renin angiotensin aldosterone system | - |
dc.subject.keywordPlus | sample size | - |
dc.subject.keywordPlus | serum | - |
dc.subject.keywordPlus | transient ischemic attack | - |
dc.subject.keywordPlus | vomiting | - |
dc.subject.keywordPlus | chronic kidney failure | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | drug effects | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | kidney | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | oral drug administration | - |
dc.subject.keywordPlus | pathophysiology | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordPlus | Administration, Oral | - |
dc.subject.keywordPlus | Carbon | - |
dc.subject.keywordPlus | Disease Progression | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Kidney | - |
dc.subject.keywordPlus | Kidney Failure, Chronic | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Oxides | - |
dc.subject.keywordPlus | Prospective Studies | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.